Abstract
Background aims
Methods
Results
Conclusions
Key Words
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to CytotherapyReferences
- Advanced therapy medicinal products: current and future perspectives.J Mark Access Health Policy. 2016 Apr 25; ([cited 2019 Jul 24];4. Available from:)
- Gene therapies development: slow progress and promising prospect.J Mark Access Health Policy. 2017 Jan 3; 5 ([cited 2019 Jul 19]Available from:)
- Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders.Front Genet. 2019; 10 ([cited 2020 Sep 27]Available from:)
- Cell & gene therapies calling for innovation in drug development.Drug Development and Delivery. 2018 Aug 27; ([cited 2020 May 19]; Available from:)
Alliance for Regenerative Medicine. 2020: Growth & Resilience in Regenerative Medicine. 2020 [cited 2021 Aug 22]. Available from: https://alliancerm.org/sector-report/2020-annual-report/
Alliance for Regenerative Medicine. Regenerative Medicine in 2021: A Year of Firsts and Records. 2020 [cited 2021 Aug 22]. Available from: https://alliancerm.org/sector-report/h1-2021-report/
Wechsler J. FDA tackles cellular, gene therapies. BioPharm International. 2016 Oct 24 [cited 2019 May 29]; Available from: http://www.biopharminternational.com/fda-tackles-cellular-gene-therapies-0
- FDA prepares for huge growth in cell and gene therapy.Chemical & Engineering News. 2019 Jan 16; 97 ([cited 2019 May 13]Available from:)
- Bristol Myers Squibb's CAR-T liso-cel wins long-delayed FDA nod.FiercePharma. 2021 Feb 5; ([cited 2021 Feb 5]; Available from:)
- Approved cellular and gene therapy products.Food and Drug Administration. 2019 Dec 20; ([cited 2020 Jan 22]; Available from:)
- FDA approves new treatment for adults with relapsed or refractory large-B-cell lymphoma.Food and Drug Administration. 2021; ([cited 2021 Feb 6]. Available from:)
BioMarin. BioMarin Receives Complete Response Letter (CRL) from FDA for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A. 2020 [cited 2020 Sep 12]. Available from: https://investors.biomarin.com/2020-08-19-BioMarin-Receives-Complete-Response-Letter-CRL-from-FDA-for-Valoctocogene-Roxaparvovec-Gene-Therapy-for-Severe-Hemophilia-A
Bristol Myers Squibb. Bristol Myers Squibb and bluebird bio Provide Regulatory Update on Idecabtagene Vicleucel (ide-cel, bb2121) for the Treatment of Patients with Multiple Myeloma. 2020 [cited 2020 Sep 12]. Available from: https://news.bms.com/news/corporate-financial/2020/Bristol-Myers-Squibb-and-bluebird-bio-Provide-Regulatory-Update-on-Idecabtagene-Vicleucel-ide-cel-bb2121-for-the-Treatment-of-Patients-with-Multiple-Myeloma/default.aspx
- Small Molecule Vs Cell Therapy Clinical Trial Supply Chain.TrakCel. 2017; (Available from:): 1-8
- Personalized Supply Chains for Cell Therapies.Cell Gene Therapy Insights. 2017; 3: 815-833
- Gene Therapy Products: Separate Regulations?.BioProcess International. 2020 Jan 31; ([cited 2020 Oct 1]; Available from:)
Novartis. Kymriah® (tisagenlecleucel) efficacy data & clinical trials. 2019 [cited 2019 Jul 19]. Available from: https://www.hcp.novartis.com/products/kymriah/acute-lymphoblastic-leukemia-children/efficacy/
Novartis. AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA). 2019 [cited 2019 Jul 19]. Available from: https://www.novartis.com/news/media-releases/avexis-receives-fda-approval-zolgensma-first-and-only-gene-therapy-pediatric-patients-spinal-muscular-atrophy-sma
Yescarta. CAR T personalized immunotherapy from YESCARTA® (axicabtagene ciloleucel). 2019 [cited 2019 Nov 6]. Available from: https://www.yescarta.com/personalized-immunotherapy#how-yescarta-works
- Why Controlling CQAs Isn't Good Enough For Gene Cell Therapies.Cell & Gene. 2020 Mar; ([cited 2020 Sep 6]; Available from:)
- Managing starting material stability to maximize manufacturing flexibility and downstream efficiency.Cell & Gene Therapy Insights. 2019; 5: 303-314
- Clinical manufacturing of CAR T cells: foundation of a promising therapy.Molecular Therapy - Oncolytics. 2016; 3: 16015
Stanton D. Dude where's my CAR-T? Personalised meds need personalised logistics, says TrakCel. biopharma-reporter.com. 2017 Aug 31 [cited 2019 May 21]; Available from: https://www.biopharma-reporter.com/Article/2017/09/01/Novartis-must-prove-it-can-handle-complex-CAR-T-supply-chain-TrakCel
- Clinical manufacturing: clearing higher hurdles.Pharmaceutical Technology. 2018 Aug 28; 42: 60-63
- Dendreon, done in by expensive, complex manufacturing, files for bankruptcy.FiercePharma. 2014; ([cited 2020 Sep 6]; Available from:)
- Multifaceted approach addresses pandemic's threat to prostate cancer care.Urology Times. 2020; ([cited 2020 Sep 7]; Available from:)
- Inside a factory churning out the latest cancer cell therapies.STAT. 2016 Dec 6; ([cited 2020 Feb 28]; Available from:)
Sawicki MW. The chain of compliance. Contract Pharma. 2018 Jun 12 [cited 2020 Mar 26]; Available from: https://www.contractpharma.com/issues/2018-06-01/view_features/the-chain-of-compliance/
- Chain of identity and chain of custody in personalized therapies - core differences from traditional pharma.Vineti. 2019 Oct 30; ([cited 2020 Apr 22]; Available from:)
- Standardizing The Vein-To-Vein Logistics Workflow To Reach More Patients.Cell & Gene. 2019; ([cited 2020 Dec 31]; Available from:)
- Unifying cell therapy logistics and manufacturing.Cytiva. 2020; ([cited 2020 Apr 22]. Available from:)
- As Needs Change, the CRO Industry Adapts.GEN - Genetic Engineering and Biotechnology News. 2020; 40 ([cited 2020 Dec 30]Available from:)
- Delivering cellular and gene therapies to patients: solutions for realizing the potential of the next generation of medicine.Gene Therapy. 2019;
- Biopharmaceutical Cold Chain Best Practices.JOC. 2018; ([cited 2019 May 5]; Available from:)
- Key considerations of cell and gene therapy cold chain logistics.Cell Gene Therapy Insights. 2016; 2: 223-236
Tavakoli F. Cryogenic transport for gene therapy products — exploring the pros and cons. 2019 Mar 21 [cited 2020 Apr 1]; Available from: https://www.cellandgene.com/doc/cryogenic-transport-for-gene-therapy-products-exploring-the-pros-and-cons-0001
- Intricate supply chain complicates gene therapy manufacturing.Cell & Gene. 2018; ([cited 2020 Apr 1]; Available from:)
- Temperature excursion management: A novel approach of quality system in pharmaceutical industry.Saudi Pharm J. 2017; 25: 176-183
- For CAR-Ts to be successful, figuring out manufacturing is key.MedCity News. 2019; ([cited 2020 Feb 28]; Available from:)
- Getting the supply chain right for biologics.World Pharma Today. 2019; ([cited 2019 Aug 21]; Available from:)
- Time- and temperature-controlled transport: supply chain challenges and solutions.P T. 2018; 43: 154-170
- Cold chain as a Service: Is outsourcing the next step for pharmaceutical logistics?.Pharma Logistics IQ. 2019; ([cited 2020 Apr 28]; Available from:)
- No-compromise cold chains.Pharma Manufacturing. 2019; ([cited 2020 Apr 28]; Available from:)
- On Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals For Human Use : Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2).in: International Conference On Harmonisation. 2015 ([cited 2019 Aug 21]. Available from:)
FDA. E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1). 2018. Available from: http://www.fda.gov/regulatory-information/search-fda-guidance-documents/e6r2-good-clinical-practice-integrated-addendum-ich-e6r1
- Good distribution practice.European Medicines Agency, 2018 ([cited 2019 Jul 10]. Available from:)
ANVISA. Página Inicial da Anvisa—Anvisa. 2019 [cited 2019 May 2]. Available from: http://portal.anvisa.gov.br/
- Main responsibilities of the National Medical Products Administration. National Medical Products Administration.2019 ([cited 2019 Apr 21]. Available from:)
- Implementation science: Key concepts, themes, and evidence for practitioners in educational psychology.Handbook of Implementation Science for Psychology in Education. 2012; : 13-34
- Designing and Conducting Survey Research: A Comprehensive Guide.4th Edition. Wiley. Wiley.com, 2021 (citedAvailable from:)
Devroe R, Wauters B. How to Enhance the External Validity of Survey Experiments? A Discussion on the Basis of an Experimental Study on Political Gender Stereotypes in Flanders (Belgium). 2019.
- A Comparison of a Postal Survey and Mixed-Mode Survey Using a Questionnaire on Patients’ Experiences With Breast Care.Journal of Medical Internet Research. 2011; 13: e68
- Survey Response Rate Levels and Trends in Organizational Research.Human Relations. 2008; 61: 1139-1160
- Questionnaire Survey Nonresponse: A comparison of postal mail and Internet surveys.International Journal of Human Computer Interaction. 2009; 25: 348-373
- Factors affecting response rates of the web survey: A systematic review.Computers in Human Behavior. 2010; 26: 132-139
Saleh A, Bista K. Examining Factors Impacting Online Survey Response Rates in Educational Research: Perceptions of Graduate Students. Vol. 13, Online Submission. 2017 [cited 2020 Sep 10]. Available from: https://eric.ed.gov/?id=ED596616
Colasante W, Pascale D, Gerlovin L. How are cell and gene therapies changing drug development models. 2018 Jul 12 [cited 2019 May 1]; Available from: https://www.cellandgene.com/doc/how-are-cell-and-gene-therapies-changing-drug-development-models-0001
- Establishing manufacturing controls: a hurdle for the cell and gene therapy industry.Regulatory Affairs Professionals Society (RAPS). 2019; ([cited 2020 Mar 29]; Available from:)
- Cell and gene therapy: Biopharma portfolio strategy.McKinsey. 2020; ([cited 2020 Oct 10]; Available from:)
- Tough Road: Cost To Develop One New Drug Is $2.6 Billion; Approval Rate for Drugs Entering Clinical Development is Less Than 12%.Policy & Medicine. 2019; ([cited 2021 Jan 3]; Available from:)
CPhI. Global Business Report Industry Explorations: UNITED STATES BIOPHARMACEUTICALS 2019. 2019 [cited 2020 Oct 7]. Available from: https://www.gbreports.com/files/pdf/_2019/US_Biopharma_2019.pdf
- Strengthening health care's supply chain: A five-step plan.McKinsey & Company. 2013; ([cited 2020 Dec 30]; Available from:)
- Top Trends in Pharmaceutical Supply Chain Costs.Definitive Healthcare. 2020; ([cited 2020 Dec 30]. Available from:)
- Even With High Costs & Uncertainty, Gene Therapy Finds Funding And Warm IPO Waters.Crunchbase News. 2017; ([cited 2020 Oct 3]. Available from:)
- Novartis bets big on gene therapy with $8.7 billion AveXis deal.Reuters. 2018; ([cited 2019 Aug 6]; Available from)
Novartis. Novartis CEO on how to price lifesaving cell and gene therapies. 2018 [cited 2019 May 13]. Available from: https://www.cnbc.com/2018/11/26/novartis-ceo-on-how-to-price-lifesaving-cell-and-gene-therapies.html
- Gilead Bets $11 Billion on New Cancer Therapy.The Wall Street Journal. 2017; ([cited 2021 Feb 4]; Available from:)
- Is COVID-19 the long overdue wake-up call for pharma supply chains?.GMP Review. 2020; 19: 4-7
- Is COVID-19 the long overdue wake-up call for pharma supply chains? Part 2.GMP Review. 2020; 19 ([cited 2020 Dec 26]Available from:)
Pelican BioThermal. 2019 Biopharma Cold Chain Logistics Survey Report. 2019 [cited 2020 Apr 28]. Available from: https://info.pelicanbiothermal.com/2019tcpsurveyreport-ty?submissionGuid=ff72290e-d7f0-4a13-aeb8-a4f9ebee981b
- Biopharma Cold Chain Sourcebook. 2018; (2018)
- Pharmaceutical Supply Chain Challenges within the Nordics, Central and Eastern Europe.World Courier, 2019 ([cited 2020 Jan 15]. Available from:)
FDA. Inspection Observations—Year 2017. FDA; 2017 [cited 2020 Dec 26]. Available from: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/inspection-observations
FDA. Inspection Observations—Year 2018. FDA; 2018 [cited 2020 Dec 26]. Available from: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/inspection-observations
FDA. Warning Letter—McKesson Corportaion. 2018 [cited 2020 Oct 11]. Available from: https://www.fda.gov/media/120780/download
FDA. Inspection Observations—Year 2019. FDA; 2019 [cited 2020 Dec 26]. Available from: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/inspection-observations
FDA. Inspection Observations—Year 2020. FDA; 2020 [cited 2020 Dec 26]. Available from: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/inspection-observations
FDA. Warning Letters. FDA. FDA; 2020 [cited 2020 Oct 11]. Available from: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters
Reed C. Establishing A Critical Supply Chain For Autologous Cell And Gene Therapies. 2018 Nov [cited 2020 Sep 7]; Available from: https://www.cellandgene.com/doc/establishing-a-critical-supply-chain-for-autologous-cell-and-gene-therapies-0001
Reed C. Does Blockchain Make Sense For The Cell & Gene Therapy Supply Chain? 2019 [cited 2020 Sep 7]; Available from: https://www.cellandgene.com/doc/does-blockchain-make-sense-for-the-cell-gene-therapy-supply-chain-0001
- The United States Pharmacopeia (USP) new chapter on the storage and distribution of investigational drug product (IDP).Pharmaceutical Outsourcing. 2016; ([cited 2020 Apr 18]; Available from:)
Hunt D. United States Pharmacopeia (USP). Updates to Supply Chain Guidelines - 1079, 1079.1 and 1083 (15). 2020.
- Project: Transportation Requirements of Cell Therapy Products.Standards Coordinating Body. 2020; ([cited 2020 Jul 1]. Available from:)
- Regenerative Medicine Standards in Development Updates: ISO.Standards Coordinating Body. 2020; ([cited 2020 Jul 1]. Available from:)
USP. Harmonized standards overview. United States Pharmacopeia; 2020 [cited 2020 May 2]. Available from: https://www.usp.org/harmonized-standards-overview
- Logistics by design: a framework for advanced therapy developers to create optimal logistics platforms.Cell Gene Therapy Insights. 2019; 4: 1019-1040
- Supply chain management in the drug industry: delivering patient value for pharmaceuticals and biologics.Wiley, Hoboken, N.J2011: 432
- Cellular and genetic therapies push into the commercial arena.Pharmaceutical Commerce. 2019; ([cited 2020 Sep 12]. Available from:) (/)
FACT. What FACT Accreditation Means To Patients. 2020 [cited 2020 Oct 3]. Available from: http://www.factwebsite.org/Inner.aspx?id=351
ISO. ISO 21973:2020 : Biotechnology—General requirements for transportation of cells for therapeutic use. 2020 [cited 2020 Oct 5]. Available from: https://www.iso.org/cms/render/live/en/sites/isoorg/contents/data/standard/07/23/72326.html
